157 related articles for article (PubMed ID: 26848655)
1. Effects of Atorvastatin Dose and Concomitant Use of Angiotensin-Converting Enzyme Inhibitors on Renal Function Changes over Time in Patients with Stable Coronary Artery Disease: A Prospective Observational Study.
Wieczorek-Surdacka E; Świerszcz J; Surdacki A
Int J Mol Sci; 2016 Feb; 17(2):. PubMed ID: 26848655
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
[TBL] [Abstract][Full Text] [Related]
3. Effect of high-dose atorvastatin on the cardiovascular risk associated with individual components of metabolic syndrome: a subanalysis of the Treating to New Targets (TNT) study.
Deedwania PC; Shepherd J; Breazna A; DeMicco DA;
Diabetes Obes Metab; 2016 Jan; 18(1):56-63. PubMed ID: 26434404
[TBL] [Abstract][Full Text] [Related]
4. Impact of high loading dose of atorvastatin in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention: a randomized controlled trial.
Shehata M; Hamza M
Cardiovasc Ther; 2015 Apr; 33(2):35-41. PubMed ID: 25677920
[TBL] [Abstract][Full Text] [Related]
5. Prevention of atherosclerosis progression using atorvastatin in normolipidemic coronary artery disease patients--a controlled randomized trial.
Shukla A; Sharma MK; Jain A; Goel PK
Indian Heart J; 2005; 57(6):675-80. PubMed ID: 16521637
[TBL] [Abstract][Full Text] [Related]
6. Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels.
Takahashi Y; Satoh M; Minami Y; Tabuchi T; Itoh T; Nakamura M
Clin Sci (Lond); 2010 Jul; 119(9):395-405. PubMed ID: 20524934
[TBL] [Abstract][Full Text] [Related]
7. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis.
Kuryata OV; Yegorova YV
Kardiol Pol; 2006 Jan; 64(1):44-8; discussion 49-50. PubMed ID: 16444629
[TBL] [Abstract][Full Text] [Related]
8. Relation Between Change in Renal Function and Cardiovascular Outcomes in Atorvastatin-Treated Patients (from the Treating to New Targets [TNT] Study).
Shepherd J; Breazna A; Deedwania PC; LaRosa JC; Wenger NK; Messig M; Wilson DJ;
Am J Cardiol; 2016 Apr; 117(8):1199-205. PubMed ID: 26940556
[TBL] [Abstract][Full Text] [Related]
9. Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study.
Ostad MA; Eggeling S; Tschentscher P; Schwedhelm E; Böger R; Wenzel P; Meinertz T; Munzel T; Warnholtz A
Atherosclerosis; 2009 Jul; 205(1):227-32. PubMed ID: 19150064
[TBL] [Abstract][Full Text] [Related]
10. Circulating Toll-like receptor 4-responsive microRNA panel in patients with coronary artery disease: results from prospective and randomized study of treatment with renin-angiotensin system blockade.
Satoh M; Takahashi Y; Tabuchi T; Tamada M; Takahashi K; Itoh T; Morino Y; Nakamura M
Clin Sci (Lond); 2015 Apr; 128(8):483-91. PubMed ID: 25385173
[TBL] [Abstract][Full Text] [Related]
11. Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy.
Undas A; Brummel-Ziedins KE; Potaczek DP; Stobierska-Dzierzek B; Bryniarski L; Szczeklik A; Mann KG
J Thromb Haemost; 2006 Nov; 4(11):2397-404. PubMed ID: 16907931
[TBL] [Abstract][Full Text] [Related]
12. Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1).
Rutter MK; Prais HR; Charlton-Menys V; Gittins M; Roberts C; Davies RR; Moorhouse A; Jinadev P; France M; Wiles PG; Gibson JM; Dean J; Kalra PA; Cruickshank JK; Durrington PN
Diabet Med; 2011 Jan; 28(1):100-8. PubMed ID: 21166851
[TBL] [Abstract][Full Text] [Related]
13. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.
Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
Clin J Am Soc Nephrol; 2007 Nov; 2(6):1131-9. PubMed ID: 17942759
[TBL] [Abstract][Full Text] [Related]
14. Treatment with triple combination of atorvastatin, perindopril, and amlodipine in patients with stable coronary artery disease: A subgroup analysis from the PAPA-CAD study.
Dézsi CA
J Int Med Res; 2018 May; 46(5):1902-1909. PubMed ID: 29557300
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of combination atorvastatin (40 mg) + ezetimibe (10 mg) versus atorvastatin (40 mg) alone on secretory phospholipase A2 activity in patients with stable coronary artery disease or coronary artery disease equivalent.
Azar M; Valentin E; Badaoui G; Kassab R; Sarkis A; Azar RR
Am J Cardiol; 2011 Jun; 107(11):1571-4. PubMed ID: 21439529
[TBL] [Abstract][Full Text] [Related]
16. Comparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled for percutaneous coronary intervention.
Ishii H; Nishio M; Takahashi H; Aoyama T; Tanaka M; Toriyama T; Tamaki T; Yoshikawa D; Hayashi M; Amano T; Matsubara T; Murohara T
Clin Ther; 2010 Dec; 32(14):2337-47. PubMed ID: 21353104
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin/ACE-inhibitor combination.
Radaelli A; Loardi C; Cazzaniga M; Balestri G; DeCarlini C; Cerrito MG; Cusa EN; Guerra L; Garducci S; Santo D; Menicanti L; Paolini G; Azzellino A; Lavitrano ML; Mancia G; Ferrari AU
Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2750-5. PubMed ID: 17823365
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease.
Uemura Y; Watarai M; Ishii H; Koyasu M; Takemoto K; Yoshikawa D; Shibata R; Matsubara T; Murohara T
J Cardiol; 2012 Jan; 59(1):50-6. PubMed ID: 22100058
[TBL] [Abstract][Full Text] [Related]
19. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.
Tsujita K; Sugiyama S; Sumida H; Shimomura H; Yamashita T; Yamanaga K; Komura N; Sakamoto K; Oka H; Nakao K; Nakamura S; Ishihara M; Matsui K; Sakaino N; Nakamura N; Yamamoto N; Koide S; Matsumura T; Fujimoto K; Tsunoda R; Morikami Y; Matsuyama K; Oshima S; Kaikita K; Hokimoto S; Ogawa H;
J Am Coll Cardiol; 2015 Aug; 66(5):495-507. PubMed ID: 26227186
[TBL] [Abstract][Full Text] [Related]
20. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
